Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026)
Biocryst Pharmaceuticals (BCRX) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -2.21% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -7.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 63.29% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1,183.78% |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.76% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -14.15% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | 23.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.27% |
| Dec 31, 2025 | -45.04% |
| Sep 30, 2025 | 1.20% |
| Jun 30, 2025 | 24.45% |
| Mar 31, 2025 | 35.61% |
| Dec 31, 2024 | 5.24% |
| Sep 30, 2024 | 38.04% |
| Jun 30, 2024 | 39.31% |
| Mar 31, 2024 | 39.57% |
| Dec 31, 2023 | 38.65% |
| Sep 30, 2023 | 86.36% |
| Mar 31, 2023 | 66.32% |
| Dec 31, 2022 | 195.03% |
| Sep 30, 2022 | 64.73% |
| Jun 30, 2022 | 42.59% |
| Mar 31, 2022 | 41.39% |
| Dec 31, 2021 | 115.11% |
| Sep 30, 2021 | 64.04% |
| Jun 30, 2021 | 85.08% |
| Mar 31, 2021 | 78.56% |